The Annual Golden Leaf Awards 2024
Sponsored exclusively by BMJ, the Golden Leaf Awards program recognizes outstanding contributions by companies associated with the global tobacco and nicotine industries. We offer multiple opportunities for industry professionals to highlight their accomplishments throughout the year.
Don’t miss this golden opportunity to recognize your company’s or another company’s outstanding performance.
The deadline for submissions is August 1, 2024.
The Golden Leaf Awards Over the Years
The court found Zest Brands is likely to succeed on claims that the FDA failed to adequately assess the impact of its 2021 PMTA regulations on small businesses.
Some farmers say they are currently bearing medical costs linked to tobacco-related ailments and accuse companies of not prioritizing worker safety.
The minister confirmed that the current framework will be maintained, keeping bidi taxation and pricing consistent with the previous fiscal year.
Experts are urging to strengthen enforcement and expand regulatory frameworks to cover both traditional tobacco and newer nicotine products.
The discussion comes amid ongoing concerns that smoking rates remain relatively high despite existing control measures.
The U.S. cigarette market was valued at $197.3 billion in 2025, while China is projected to expand at a 4.2% CAGR to $162.5 billion by 2032.
The company reported a closing price of $6.91 per share and approximately 160.39 million ordinary shares outstanding.
The coalition argued that nicotine-related sponsorships connected to Formula 1 teams and events could expose younger audiences to marketing for addictive products.
The court’s decision is expected to clarify the scope of municipal “home rule” powers in Ohio and could influence how local governments regulate a range of industries and products.
The growth of unauthorized vape sales emerged as a key issue, with participants calling for stronger enforcement.
The company said it strengthened liquidity and operations over the past year, including the $7.5 million sale of 16 PMTA-authorized products.
Researchers cited in the report raise concerns about industry-funded studies and communications shaping cannabis narratives.
The article concludes that the DOD must better align clinical policy with operational reality to maintain credibility.
The update broadens the brand’s existing strength architecture in the market, which now spans 1.5mg, 3mg and 6mg across multiple flavors.
The company’s appeal is being driven by both capital returns and strong operating performance.